Epinephrine Microarray Patch Equipment Supply
쿼드메디슨
464490
Signal Score
Historical Avg Return (5d)
+0.15%
Data Coverage
100%n=723
Risk-adjusted indicator based on 723 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Amount: 6,000,000,000 KRW
- • % of Recent Revenue: 56.1%
- • Contract Start Date: 2026-05-15
- • Contract End Date: 2027-03-31
- • Down Payment: 3,000,000,000 KRW
AI Analysis Summary
QuadMedicine Inc. signed a conditional contract with Hanlim Pharm Co., Ltd. to supply epinephrine microarray patch production equipment, valued at 6,000,000,000 KRW. This contract represents 56.1% of the company's recent annual revenue (2025). The payment schedule includes a 3,000,000,000 KRW down payment in Q2 2026, 2,500,000,000 KRW in Q4 2026, and a final 500,000,000 KRW in Q1 2027. The contract period is from May 15, 2026, to March 31, 2027. This significant contract is expected to have a positive financial impact.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.